Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03346668 · ClinicalTrials.gov registry record · Early Phase 1
Role of Neurogenic Inflammation and Topical 6% Gabapentin Therapy in Symptomatic Scarring Alopecia
A Early Phase 1 study, sponsored by University of Minnesota.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 5
- Enrollment target
NCT03346668 is a Early Phase 1 study that has completed, run by University of Minnesota. The registered enrollment target is 5 participants.
The verdict
NCT03346668, a Early Phase 1 study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This study will serve as a pilot study to determine the efficacy and safety of topical gabapentin in the treatment of symptomatic scarring alopecia.
Interventions
- DRUG Topical gabapentin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2016-01-28 |
| Est. Completion | 2021-10-11 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03346668
The ClinicalTrials.gov registry entry for NCT03346668 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Topical gabapentin is the first listed.
NCT03346668 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03346668 about?
NCT03346668 is a clinical study titled "Role of Neurogenic Inflammation and Topical 6% Gabapentin Therapy in Symptomatic Scarring Alopecia". This study will serve as a pilot study to determine the efficacy and safety of topical gabapentin in the treatment of symptomatic scarring alopecia.
What is the current status of trial NCT03346668?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 5 participants. The study started on 2016-01-28. Estimated completion is 2021-10-11.
What interventions are being tested in trial NCT03346668?
The interventions under investigation include: Topical gabapentin (DRUG).
Who is sponsoring clinical trial NCT03346668?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.